Cyclo Therapeutics Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
CYTH Nasdaq 2833 https://www.cyclotherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyclo Therapeutics Inc

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results - Mar 20th, 2023 12:05 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th - Jan 11th, 2023 6:00 pm
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements - Jan 11th, 2023 1:05 pm
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event - Jan 10th, 2023 1:05 pm
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease - Jan 9th, 2023 1:05 pm
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Jan 4th, 2023 9:05 pm
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting - Jan 4th, 2023 1:05 pm
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Dec 30th, 2022 1:00 pm
Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements - Nov 11th, 2022 1:05 pm
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1) - Oct 18th, 2022 12:05 pm
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease - Oct 4th, 2022 12:05 pm
Cyclo Therapeutics Provides Business Update - Sep 28th, 2022 6:02 pm
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 7th, 2022 12:05 pm
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results - Aug 16th, 2022 12:05 pm
Cyclo Therapeutics to Present at the China NPC Association Meeting - Aug 8th, 2022 12:05 pm
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022 - Jul 21st, 2022 12:05 pm
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate - Jul 12th, 2022 11:30 am
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022 - Jul 11th, 2022 12:05 pm
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation - Jun 21st, 2022 12:05 pm
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference - May 18th, 2022 12:00 pm